GB0214149D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB0214149D0
GB0214149D0 GBGB0214149.7A GB0214149A GB0214149D0 GB 0214149 D0 GB0214149 D0 GB 0214149D0 GB 0214149 A GB0214149 A GB 0214149A GB 0214149 D0 GB0214149 D0 GB 0214149D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
solvate
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0214149.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0214149.7A priority Critical patent/GB0214149D0/en
Publication of GB0214149D0 publication Critical patent/GB0214149D0/en
Priority to RU2004135539/04A priority patent/RU2323929C2/ru
Priority to CNA03819290XA priority patent/CN1674897A/zh
Priority to BR0311931-9A priority patent/BR0311931A/pt
Priority to PCT/EP2003/006415 priority patent/WO2004000315A1/en
Priority to CA002487909A priority patent/CA2487909A1/en
Priority to IL16547603A priority patent/IL165476A0/xx
Priority to MXPA04012857A priority patent/MXPA04012857A/es
Priority to JP2004514761A priority patent/JP2005534672A/ja
Priority to PL03375148A priority patent/PL375148A1/xx
Priority to SI200331089T priority patent/SI1513526T1/sl
Priority to HK05107902.7A priority patent/HK1076712B/en
Priority to KR1020047020583A priority patent/KR20050030624A/ko
Priority to AU2003245962A priority patent/AU2003245962B2/en
Priority to EP03738056A priority patent/EP1513526B1/en
Priority to AT03738056T priority patent/ATE377420T1/de
Priority to DK03738056T priority patent/DK1513526T3/da
Priority to ES03738056T priority patent/ES2295601T3/es
Priority to NZ537210A priority patent/NZ537210A/en
Priority to PT03738056T priority patent/PT1513526E/pt
Priority to DE60317326T priority patent/DE60317326T2/de
Priority to US10/518,679 priority patent/US7338960B2/en
Priority to IS7574A priority patent/IS7574A/is
Priority to NO20045328A priority patent/NO20045328L/no
Priority to ZA200410061A priority patent/ZA200410061B/en
Priority to CY20081100116T priority patent/CY1107168T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
GBGB0214149.7A 2002-06-19 2002-06-19 Chemical compounds Ceased GB0214149D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB0214149.7A GB0214149D0 (en) 2002-06-19 2002-06-19 Chemical compounds
US10/518,679 US7338960B2 (en) 2002-06-19 2003-06-18 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators
KR1020047020583A KR20050030624A (ko) 2002-06-19 2003-06-18 Ｈｐｐａｒ 활성화제로서 사용되는 페닐알칸산 및페닐옥시알칸산 유도체
EP03738056A EP1513526B1 (en) 2002-06-19 2003-06-18 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
BR0311931-9A BR0311931A (pt) 2002-06-19 2003-06-18 Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente
PCT/EP2003/006415 WO2004000315A1 (en) 2002-06-19 2003-06-18 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
CA002487909A CA2487909A1 (en) 2002-06-19 2003-06-18 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
IL16547603A IL165476A0 (en) 2002-06-19 2003-06-18 Phenylalkanoic acid and phenyloxanoic acid derivatives as hppar activators
MXPA04012857A MXPA04012857A (es) 2002-06-19 2003-06-18 Derivados de acido fenilalcanoico y de acido feniloxialcanoico como activadores de receptores activados del proliferador de peroxisoma humano (hppar).
JP2004514761A JP2005534672A (ja) 2002-06-19 2003-06-18 ｈＰＰＡＲ活性化物質としてのフェニルアルカン酸及びフェニルオキシアルカン酸誘導体
PL03375148A PL375148A1 (en) 2002-06-19 2003-06-18 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
SI200331089T SI1513526T1 (sl) 2002-06-19 2003-06-18 Fenilalkanojska kislina in derivati feniloksialkanojske kisline kot hPPAR aktivatorji
HK05107902.7A HK1076712B (en) 2002-06-19 2003-06-18 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
RU2004135539/04A RU2323929C2 (ru) 2002-06-19 2003-06-18 Производные фенилалкановой кислоты и фенилоксиалкановой кислоты, их применение и содержащая их фармацевтическая композиция
AU2003245962A AU2003245962B2 (en) 2002-06-19 2003-06-18 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators
CNA03819290XA CN1674897A (zh) 2002-06-19 2003-06-18 作为hppar激活剂的苯基链烷酸和苯氧基链烷酸衍生物
AT03738056T ATE377420T1 (de) 2002-06-19 2003-06-18 Phenylalkansäure- und phenyloxyalkansäure- derivate als hppar aktivatore
DK03738056T DK1513526T3 (da) 2002-06-19 2003-06-18 Phenylalkansyre- og phenyloxyalkansyrederivater som hPPAR-aktivatorer
ES03738056T ES2295601T3 (es) 2002-06-19 2003-06-18 Acido fenilalcanoico y derivados de acido feniloxialcanoico como activadores de hppar.
NZ537210A NZ537210A (en) 2002-06-19 2003-06-18 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as HPPAR activators
PT03738056T PT1513526E (pt) 2002-06-19 2003-06-18 ¿derivados de ácido fenilalcanóico e de ácido feniloxialcanóico como activadores de hppar¿
DE60317326T DE60317326T2 (de) 2002-06-19 2003-06-18 Phenylalkansäure- und phenyloxyalkansäure-derivate als hppar aktivatore
IS7574A IS7574A (is) 2002-06-19 2004-11-30 Fenýlalkanósýra og fenýloxýalkanósýru afleiður sem HPPAR virkjar
NO20045328A NO20045328L (no) 2002-06-19 2004-12-03 Fenylalkansyre og fenyloksyalkansyrederivater som HPPAR-aktivatorer
ZA200410061A ZA200410061B (en) 2002-06-19 2004-12-13 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR acivators
CY20081100116T CY1107168T1 (el) 2002-06-19 2008-01-31 Παραγωγα φαινυλοαλκανοϊκου οξεος και φαινυλοξυαλκανοϊκου οξεος ως ενεργοποιηται hppar

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0214149.7A GB0214149D0 (en) 2002-06-19 2002-06-19 Chemical compounds

Publications (1)

Publication Number Publication Date
GB0214149D0 true GB0214149D0 (en) 2002-07-31

Family

ID=9938916

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0214149.7A Ceased GB0214149D0 (en) 2002-06-19 2002-06-19 Chemical compounds

Country Status (25)

Country Link
US (1) US7338960B2 (https=)
EP (1) EP1513526B1 (https=)
JP (1) JP2005534672A (https=)
KR (1) KR20050030624A (https=)
CN (1) CN1674897A (https=)
AT (1) ATE377420T1 (https=)
AU (1) AU2003245962B2 (https=)
BR (1) BR0311931A (https=)
CA (1) CA2487909A1 (https=)
CY (1) CY1107168T1 (https=)
DE (1) DE60317326T2 (https=)
DK (1) DK1513526T3 (https=)
ES (1) ES2295601T3 (https=)
GB (1) GB0214149D0 (https=)
IL (1) IL165476A0 (https=)
IS (1) IS7574A (https=)
MX (1) MXPA04012857A (https=)
NO (1) NO20045328L (https=)
NZ (1) NZ537210A (https=)
PL (1) PL375148A1 (https=)
PT (1) PT1513526E (https=)
RU (1) RU2323929C2 (https=)
SI (1) SI1513526T1 (https=)
WO (1) WO2004000315A1 (https=)
ZA (1) ZA200410061B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1667964B1 (en) 2003-09-19 2009-07-22 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
CN1875002B (zh) 2003-11-05 2011-08-03 霍夫曼-拉罗奇有限公司 作为ppar激动剂的苯基衍生物
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP5299810B2 (ja) * 2004-02-27 2013-09-25 アムジエン・インコーポレーテツド 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法
AR048523A1 (es) * 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
CA2646430A1 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
UY30288A1 (es) 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
CN101591227B (zh) * 2006-06-23 2012-09-05 赵昱 一类肉桂醇类衍生物及其制备方法和药物用途
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
AU2007292816B2 (en) * 2006-09-07 2011-11-17 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
US8519145B2 (en) 2006-12-02 2013-08-27 Seoul National University Industry Foundation Aryl compounds as PPAR ligands and their use
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
JP5291708B2 (ja) * 2007-07-25 2013-09-18 中国人民解放軍軍事医学科学院毒物薬物研究所 アリールピリミジン誘導体、その製造方法、及び、その使用
CN102083783A (zh) 2007-10-10 2011-06-01 安姆根有限公司 取代的联苯gpr40调节剂
WO2009111056A1 (en) * 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
EP2699569B1 (en) * 2011-04-22 2017-08-30 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
NZ631569A (en) 2012-02-28 2016-10-28 Piramal Entpr Ltd Phenyl alkanoic acid derivatives as gpr agonists
KR101569522B1 (ko) 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
CN108503581A (zh) * 2018-04-12 2018-09-07 苏州康润医药有限公司 一种3-溴-6-氟-2-吡啶乙酮的合成方法
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS175831B1 (https=) * 1974-12-17 1977-05-31
FR2401459A1 (fr) * 1977-08-26 1979-03-23 Cii Honeywell Bull Support d'information portatif muni d'un microprocesseur et d'une memoire morte programmable
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
US6204277B1 (en) * 1996-08-19 2001-03-20 Japan Tobacco Inc. Propionic acid derivatives and applications thereof
WO1999011255A1 (en) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Peroxisome proliferator-activated receptor controllers
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6586475B1 (en) * 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
EP1177176B1 (en) * 1999-04-28 2006-04-19 Aventis Pharma Deutschland GmbH Tri-aryl acid derivatives as ppar receptor ligands
WO2001036351A2 (en) * 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
CN1251671C (zh) * 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂

Also Published As

Publication number Publication date
CA2487909A1 (en) 2003-12-31
PL375148A1 (en) 2005-11-28
NZ537210A (en) 2006-09-29
ES2295601T3 (es) 2008-04-16
RU2004135539A (ru) 2005-08-10
RU2323929C2 (ru) 2008-05-10
US7338960B2 (en) 2008-03-04
US20060089394A1 (en) 2006-04-27
AU2003245962B2 (en) 2008-07-03
AU2003245962A1 (en) 2004-01-06
CY1107168T1 (el) 2012-10-24
JP2005534672A (ja) 2005-11-17
EP1513526A1 (en) 2005-03-16
MXPA04012857A (es) 2005-02-24
KR20050030624A (ko) 2005-03-30
PT1513526E (pt) 2008-02-12
WO2004000315A1 (en) 2003-12-31
CN1674897A (zh) 2005-09-28
SI1513526T1 (sl) 2008-04-30
IS7574A (is) 2004-11-30
DE60317326T2 (de) 2008-08-28
ATE377420T1 (de) 2007-11-15
EP1513526B1 (en) 2007-11-07
IL165476A0 (en) 2006-01-15
DK1513526T3 (da) 2008-03-17
NO20045328L (no) 2005-03-09
BR0311931A (pt) 2005-04-05
ZA200410061B (en) 2006-07-26
HK1076712A1 (en) 2006-01-27
DE60317326D1 (de) 2007-12-20

Similar Documents

Publication Publication Date Title
GB0214149D0 (en) Chemical compounds
GB0214139D0 (en) Chemical compounds
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
AU2003229953A8 (en) Phthalazinone derivatives
WO2005074642A3 (en) Chemical compounds
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
WO2003082205A3 (en) Compounds and methods
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
NO20054669L (no) Substituerte kinobenzoxazinanaloger
ECSP056104A (es) Compuestos heterociclicos inmunomoduladores
AU2003223340A1 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
GB0403148D0 (en) Chemical compounds
GB0212410D0 (en) Organic compounds
GB0215392D0 (en) Chemical compounds
SG149005A1 (en) Process for the preparation of thiazolopyrimidines
TW200518748A (en) Chemical compounds
DE602004011064D1 (en) Antitrombotische aether
WO2004103305A3 (en) Spiropyrazole compound
HK1080462A (en) Novel heterocyclic analogs of diphenylethylene compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)